Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.53) by 8.5 percent. The company reported quarterly sales of $139.494 million which beat the analyst consensus estimate of $135.794 million by 2.72 percent. This is a 42.27 percent increase over sales of $98.052 million the same period last year.